A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study

References

• World Health OrganizationConsolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Available from: http://www.who.int/hiv/pub/guidelines/arv2013/en/Accessed August 17, 2015
   Google Scholar
• European AIDS Clinical Society (EACS) Guidelines. European AIDS Clinical Society (EACS) Available from: http://eacsociety.org/Portals/0/Guidelines_Online_131014.pdfAccessed August 17, 2015
   Google Scholar
• SungkanuparphSTechasathitWUtaipiboonCThai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010Asian Biomed201044515528
   Web of Science ®Google Scholar
• ShahMDBaldersonKA manic episode associated with efavirenz therapy for HIV infectionAIDS200317111713171412853762
   PubMed Web of Science ®Google Scholar
• MarzoliniCTelentiADecosterdLAEfavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patientsAIDS2001151717511192870
   PubMed Web of Science ®Google Scholar
• Sanchez-CondeMPalaciosRSanzJEfficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI studyAIDS Res Hum Retroviruses200723101237124117961110
   PubMed Web of Science ®Google Scholar
• RakhmaninaNYvan den AnkerJNEfavirenz in the therapy of HIV infectionExpert Opin Drug Metab Toxicol2010619510320001610
   PubMed Web of Science ®Google Scholar
• GutierrezFNavarroAPadillaSPrediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoringClin Infect Dis200541111648165316267739
   PubMed Web of Science ®Google Scholar
• HasseBGunthardHFBleiberGKrauseMEfavirenz intoxication due to slow hepatic metabolismClin Infect Dis2005403e22e2315668854
   PubMed Web of Science ®Google Scholar
• DjabaroutiSBreilhDPellegrinIIntracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study)J Antimicrob Chemother20065851090109316921181
   PubMed Web of Science ®Google Scholar
• Rodriguez-NovoaSBarreiroPJimenez-NacherISorianoVOverview of the pharmacogenetics of HIV therapyPharmacogenomics J20066423424516462814
   PubMed Web of Science ®Google Scholar
• MaJDLeeKCKuoGMHLA-B*5701 testing to predict abacavir hypersensitivityPLoS Curr20102RRN120321151380
   PubMedGoogle Scholar
• HaasDWGebretsadikTMayoGAssociations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americansJ Infect Dis2009199687288019239339
   PubMed Web of Science ®Google Scholar
• UttayamakulSLikanonsakulSManosuthiWEffects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adultsAIDS Res Ther20107820338069
   PubMed Web of Science ®Google Scholar
• MichaudVBar-MagenTTurgeonJFlockhartDDestaZWainbergMAThe dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and dispositionPharmacol Rev201264380383322759796
   PubMed Web of Science ®Google Scholar
• HaasDWRibaudoHJKimRBPharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group studyAIDS200418182391240015622315
   PubMed Web of Science ®Google Scholar
• TsuchiyaKGatanagaHTachikawaNHomozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimensBiochem Biophys Res Commun200431941322132615194512
   PubMed Web of Science ®Google Scholar
• ManosuthiWSukasemCLueangniyomkulAImpact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patientsAntimicrob Agents Chemother20135721019102423254426
   PubMed Web of Science ®Google Scholar
• GatanagaHHayashidaTTsuchiyaKSuccessful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26Clin Infect Dis20074591230123717918089
   PubMed Web of Science ®Google Scholar
• SukasemCCresseyTRPrapaithongPPharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adultsBr J Clin Pharmacol20127461005101222471906
   PubMed Web of Science ®Google Scholar
• SukasemCChamnanphonMKoomdeeNHigh plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infectionsDrug Metab Pharmacokinet201328539139723399569
   PubMed Web of Science ®Google Scholar
• ManosuthiWSungkanuparphSTantanathipPA randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R StudyClin Infect Dis200948121752175919438397
   PubMed Web of Science ®Google Scholar
• CsajkaCMarzoliniCFattingerKPopulation pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infectionClin Pharmacol Ther2003731203012545140
   PubMed Web of Science ®Google Scholar
• SanchezACabreraSSantosDPopulation pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patientsAntimicrob Agents Chemother201155115314532421896912
   PubMed Web of Science ®Google Scholar
• PretoriusEKlinkerHRosenkranzBThe role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infectionTher Drug Monit201133326527421566505
   PubMed Web of Science ®Google Scholar
• PfisterMLabbeLHammerSMPopulation pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: adult AIDS Clinical Trial Group Study 398Antimicrob Agents Chemother200347113013712499180
   PubMed Web of Science ®Google Scholar
• SukasemCManosuthiWKoomdeeNLow level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphismInfection201442346947424293076
   PubMed Web of Science ®Google Scholar
• ManosuthiWSukasemCThongyenSNilkamhangSManosuthiSSungkanuparphSCYP2B6 18492T→C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1Antimicrob Agents Chemother20145842268227324492364
   PubMed Web of Science ®Google Scholar
• ClevenberghPMoulySSellierPImproving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician’s point of viewCurr HIV Res2004230932115544452
   PubMed Web of Science ®Google Scholar
• FabbianiMBraccialeLRagazzoniERelationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failureInfection201139656356921866336
   PubMed Web of Science ®Google Scholar
• PulsRAminJLossoMEfficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trialLancet201438399271474148224522178
   PubMed Web of Science ®Google Scholar